Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines

Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shixia, Chou, Te-hui, Hackett, Anthony, Efros, Veronica, Wang, Yan, Han, Dong, Wallace, Aaron, Chen, Yuxin, Hu, Guangnan, Liu, Shuying, Clapham, Paul, Arthos, James, Montefiori, David, Lu, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718816/
https://www.ncbi.nlm.nih.gov/pubmed/28933684
http://dx.doi.org/10.1080/21645515.2017.1380137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718816/
https://www.ncbi.nlm.nih.gov/pubmed/28933684
http://dx.doi.org/10.1080/21645515.2017.1380137

Ejemplares similares